Brian is an expert finance leader with more than 20 years of global experience with fast-growing biotechnology companies. He joins Jnana from Momenta Pharmaceuticals where he led Financial Planning & Analysis. Previously, he served for more than 20 years in roles of increasing responsibility at Sanofi Genzyme. His most recent position at Sanofi Genzyme was Head of Finance for North America Rare Disease and Rare Blood Disorders, and he drove all aspects of strategic financial planning and operations for the North American region for two business units representing $2B in combined sales with over 500 employees and 12 products. In his roles at Sanofi Genzyme, Brian spearheaded the integration of the Bioverativ and Ablynx acquisitions, implemented financial modeling, and assembled franchise performance metrics for investor audiences. Earlier in his career, he held financial positions at Blue Cross Blue Shield of Massachusetts and KPMG. He earned a B.S. in accounting from Boston College.
Mark brings more than 17 years of biotech experience to Jnana working in multiple chemistry, manufacturing and controls (CMC) roles from pre-IND to NDA and post-commercial optimization. Prior to Jnana, Mark was the head of CMC at MapLight Therapeutics where he led the pharmaceutical development of multiple small-molecule assets in CNS disorders, including an extended-release fixed-dose combination product. During his time at MapLight, he guided the team through a period of significant growth and was part of multiple successful regulatory submissions. Prior to MapLight, Mark helped launch Zilretta® at Flexion Therapeutics and led post-commercialization process optimization and scale-up efforts and spent over nine years at Infinity Pharmaceuticals holding roles of increasing responsibility in CMC and translational science. Mark holds a master’s degree in pharmaceutical science from Northeastern University and a B.S. in chemistry from Eastern Nazarene College.
Ted brings many years of experience in accounting and financial reporting for rapidly evolving biotechnology companies. Most recently he was VP Finance, Accounting and Treasury at Xilio Therapeutics in Waltham, and prior to that he worked in a similar capacity at research and commercial biopharmaceutical companies such as Evelo Biosciences, TESARO, AMAG Pharmaceuticals and Praecis Pharmaceuticals. Ted spent the first several years of his career at KPMG, an independent public accounting firm, and obtained his MSA/MBA from Northeastern University and BSBA from Georgetown University.
Derek is Vice President and Head of Business Development at Jnana and brings his experience in business development and strategy from large and small biopharmaceutical organizations to Jnana.
Prior to joining Jnana, Derek held roles of increasing responsibility in business development at Biogen, where he was responsible for all aspects of deal evaluation, negotiation, and execution for varied transactions ranging from discovery through late stage, including collaborations, licenses, and strategic investments. He also previously spent time in business development with Nimbus Therapeutics.
Derek holds an MBA from the MIT Sloan School of Management, MS in biological sciences from the Icahn School of Medicine at Mount Sinai, and BS in biology from Boston College.
Toby joins Jnana as Vice President, Head of Clinical Operations with over 30 years of experience in all phases of global pharmaceutical and device development across multiple therapeutic areas, including over 25 years in Clinical Operations. Other areas of experience include Preclinical Safety Assessment, Regulatory Affairs and Medical Affairs leading Advisory Boards and providing Medical Scientific Liaison training and development. Before joining Jnana, Toby served as Vice President of Clinical Operations at Sio Gene Therapies. Prior to that, he was Vice President of Clinical Development at Liquidia Technologies. He has been responsible for building Clinical Operations organizations from the ground up – hiring talent, developing infrastructure, and providing management and oversight of clinical trials and programs – for several companies, including Liquidia Technologies, Exact Sciences, Actavis, Warner Chilcott Pharmaceuticals, and Procter and Gamble Pharmaceuticals. His responsibilities have also included the assessment of new technologies and process to drive innovation and efficiency into clinical development programs and lead the vetting and selection of preferred vendors and systems. Toby holds an M.S. degree in Clinical Pharmacology from The Ohio State University School of Medicine, and a B.S. in Biology from Xavier University.